Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06441968 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT06441968 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 60 participants.
The verdict
NCT06441968, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
A clinical trial to evaluate the safety, reactogenicity, and immunogenicity of MPV/S-2P administered intranasally to adults who have previously received a primary series and at least one booster with an authorized or licensed mRNA SARS-CoV-2 parenteral vaccine. The primary objective is to evaluate the safety and reactogenicity of a single dose of MPV/S-2P in previously vaccinated healthy adults.
Interventions
- BIOLOGICAL MPV/S-2P
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2025-11-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06441968
The ClinicalTrials.gov registry entry for NCT06441968 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MPV/S-2P is the first listed.
NCT06441968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06441968 about?
NCT06441968 is a clinical study titled "Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults". A clinical trial to evaluate the safety, reactogenicity, and immunogenicity of MPV/S-2P administered intranasally to adults who have previously received a primary series and at least one booster with an authorized or licensed mRNA SARS-CoV-2 parenteral vaccine. The primary objective is to evaluate t...
What is the current status of trial NCT06441968?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-07-01. Estimated completion is 2025-11-12.
What interventions are being tested in trial NCT06441968?
The interventions under investigation include: MPV/S-2P (BIOLOGICAL).
Who is sponsoring clinical trial NCT06441968?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.